{"id":40032,"date":"2021-02-24T07:28:11","date_gmt":"2021-02-24T07:28:11","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40032"},"modified":"2021-02-26T12:56:19","modified_gmt":"2021-02-26T12:56:19","slug":"novavax-90-efficacy-in-uk-but-60-in-south-africa-hints-of-lower-effect-in-hiv-positive-participants","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40032","title":{"rendered":"Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants"},"content":{"rendered":"

<\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n

On 28 January 2021, Novavax released preliminary top-line results from two studies using it\u2019s NVX-CoV2373 spike protein-based vaccine candidate. [1]<\/strong><\/p>\n

This was at the same time as concern about the B.1.351 variant first started to dominate news in the UK. [1]<\/p>\n

The phase 3 study run in the UK enrolled more than 15,000 participants between 18-84 years of age, including 27% over the age of 65. It reported 89.3% efficacy (95% CI: 75.2 to 95.4), based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19, at least 7 days after the second study vaccination.<\/p>\n

This analysis was based on 62 cases, 56 vs 6 in the placebo vs active group, respectively. Of the 62 cases, 61 were mild or moderate, and 1 was severe (in placebo group). Approximately half the cases were the B.1.1.7 variant and a post hoc analysis calculated 95.6% efficacy against the original COVID-19 strain and 85.6% against B.1.1.7.<\/p>\n

Results from a phase 2b study in 4,400 participants in South Africa reported 60% efficacy (95% CI: 19.9 to 80.1) in the 94% of participants who were HIV negative. This was based on 44 cases in 2,536 participants: 29 vs 15 in the placebo vs active groups, respectively. Data available for 27\/44 showed 92% to be the B.1.3.5.1 variant.<\/p>\n

However, when results from the 148 (6%) of HIV positive participants were added, overall efficacy dropped to 49.4% (95% CI: 6.1 to 72.8). This was due to worse outcomes in the vaccine group: 2.6% vs 5.5% had symptoms in the placebo vs active group. Although these figures are in the wrong direction, the wide confidence intervals means this might not be a real effect.<\/p>\n

Importantly. roughly one-third of the 4,400 participants (not included in the analysis) were seropositive at baseline indicating previous COVID-19 infection. This was likely the pre-variant strain, but most infections during the study were with the B.1.351 variant. So although the vaccine provided sginificant although not complete protection against the B.1.351 variant.<\/p>\n

Reference<\/p>\n

Novavax press statement. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. (28 January 2021).
\nhttps:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base On 28 January 2021, Novavax released preliminary top-line results from two studies using it\u2019s NVX-CoV2373 spike protein-based vaccine candidate. [1] This was at the same time as concern about the B.1.351 variant first started to dominate …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40032","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40032"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40032\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}